ClinicalTrials.gg
CompletedNCT03747939FOREMOSTUpdated Sep 11, 2026Results posted

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

A Phase 4 interventional study of Apremilast (CC-10004) and Apremilast (CC-10004) Placebo in Arthritis, Psoriatic, sponsored by Amgen. Completed at 114 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
5th of 17
310 · median 219
Started
2018
with 1 other
Phase 4
5 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 4, and was the 10th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.

03

Conditions studied

  • Arthritis, Psoriatic

Keywords

  • Oligoarthritis
  • PsA
  • Apremilast
  • Oral tablet
  • Background therapy
  • Standard of care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 yrs, male or female subject
  • Subjects must have signs and symptoms of PsA ≤5 years duration at the time of the Screening Visit
  • SJC AND TJC must be >1 and ≤ 4
  • For all regions, the local Regulatory Label for treatment with apremilast must be followed.
  • Stable doses of protocol-allowed PsA medications
  • General good health (except for psoriatic arthritis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (Note: The definition of good health means a subject does not have uncontrolled significant comorbid conditions).
  • Comply with protocol-required measures
  • Subject meets the Classification Criteria for Psoriatic Arthritis [CASPAR] Criteria for PsA at the Screening visit

Exclusion criteria

Exclusion Criteria:

  • Prior use of >2 csDMARD to treat PsA
  • Prior exposure to a JAK-inhibitor and/or a biologic DMARD.
  • Use of intra-articular (IA) or intra-muscular (IM) injection within 8 weeks before the Baseline Visit.
  • Use of leflunomide within 12 weeks of randomization. Subjects who stopped leflunomide and completed 11 days of treatment with cholestyramine (8 g, 3 x daily) prior to the Baseline Visit may enter the study.
  • Prior use of cyclosporine.
  • Prior treatment with apremilast, or participation in a clinical study, involving apremilast.
  • Use of any drug within 4 weeks of the Baseline Visit, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD

    Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications

    Drug: Apremilast (CC-10004)

  • Placebo comparator
    Placebo

    Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.

    Other: Apremilast (CC-10004) Placebo

Interventions

  • Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive "dummy" titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles.

    Also known as: Otezla

  • OtherApremilast (CC-10004) Placebo

    Subjects randomized to placebo will receive "dummy" dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16

    MDA is defined as tender joint counts (TJC) ≤ 1 and SJC ≤ 1 plus 3 of the following 5 criteria: 1. psoriasis body surface area (BSA) ≤ 3% 2. patient's pain visual analogue scale (VAS) on a 100 mm scale ≤ 15; where 0 indicates 'no pain' and 100 indicates 'pain as severe as can be imagined' 3. patient's global assessment of disease activity on a 100 mm scale ≤ 20, where 0 represents the lowest level of disease activity and 100 represents the highest. 4. physical function assessed by Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5; where 0 represents normal or no difficulty and 3 represents an inability to perform 5. enthesitis count ≤ 1 based on the Leeds Enthesitis Index; where 0 means nontender and 6 indicates 6 tender tendon insertions.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved Remission or Low Disease Activity at Week 16 Based on Clinical Activity in Psoriatic Arthritis (cDAPSA)

    The cDAPSA score is based on the numerical summation of 4 disease activity variables: tender and swollen joints, patient's global assessments of disease activity and assessment of pain (VAS). The cDAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. cDAPSA remission is defined as a DAPSA score ≤ 4 and low disease activity is defined as a cDAPSA score \> 4 but ≤ 13).

    Time frame: Week 16

  2. Percentage of Participants With SJC ≤ 1 at Week 16

    The SJC was based on 66 joints and at week 16 is based on the sentinel joints (i.e., the joints that were affected at baseline). A SJC response is defined as a count ≤ 1.

    Time frame: Week 16

  3. Percentage of Participants With TJC ≤ 1 at Week 16

    The TJC was based on 68 joints and at week 16 was based on the sentinel joints (i.e., the joints that were affected at baseline). A TJC response is defined as a count ≤ 1.

    Time frame: Week 16

  4. Percentage of Participants With Patient's Global Assessments of Disease Activity Score of ≤ 20 mm in the VAS at Week 16

    The Patient's Global Assessments of Disease Activity is an assessment of how active a participant's psoriatic arthritis was on average during the last week. It was assessed on a VAS ranging from 0 to 100 mm, with a higher score indicating more disease activity. A response is defined as a score ≤ 20 mm.

    Time frame: Week 16

  5. Percentage of Participants With an Assessment of Pain Score ≤ 15 mm in VAS at Week 16

    The Patients Pain VAS is the participant's assessment of how much pain they had, on average, during the last week in their joints due to psoriatic arthritis. The VAS score ranges from 0 to 100 mm, with a higher score indicating more pain.

    Time frame: Week 16

  6. Change From Baseline in Psoriatic Arthritis Impact of Disease 12-item for Clinical Trials (PsAID-12) Questionnaire Score at Week 16

    The PsAID-12 Questionnaire is a 12-item, self-administered questionnaire that reflects the impact of psoriatic arthritis from the perspective of the participant. The overall score ranges from 0 (best status) to 10 (worst status), with a cut-off ≤ 4 representing patient-acceptable symptom state. Analysis was based on a mixed-effects model for repeated measures (MMRM), which included treatment group, time, treatment group by time interaction, prior/concomitant use of csDMARD (naive, prior use only, both prior and concomitant use) and baseline glucocorticosteroid use (yes/no) per IWRS data as factors, and baseline value as a covariate.

    Time frame: Baseline and Week 16

  7. Percentage of Participants With a Good or Moderate Psoriatic Arthritis Disease Activity (PASDAS) Score at Week 16

    The PASDAS is a weighted index comprising assessments of joints, function, acute-phase response, quality of life, and patient and physician VAS. The score range of the PASDAS is 0 - 10, with worse disease activity represented by higher scores. A good response is defined as a PASDAS score of ≤ 3.2 with improvement from baseline ≥ 1.6 points. A moderate response is defined as a PASDAS score \> 3.2 with improvement from baseline ≥ 1.6 points; or PASDAS score \< 5.4 with improvement from baseline ≥ 0.8 but \< 1.6 points.

    Time frame: Baseline and Week 16

07

Results

Posted Jan 5, 2024

Participant flow

Participants were enrolled at 80 study centers in Austria, Belgium, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States from 31 December 2018 to the last participant's last study visit on 05 July 2023.

Placebo-controlled Phase (Weeks 0 - 24)
Participant flow — Placebo-controlled Phase (Weeks 0 - 24)
MilestonePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast-extension Phase: Placebo Then Apremilast 30 mgApremilast-extension Phase: Continued Apremilast 30 mg
Started10520300
Full analysis set10520300
Safety analysis set10420400
Escaped early at week 16242100
Completed week 16 and continued9217200
Completed8716200
Not completed184100
Withdrew: Death0100
Withdrew: Adverse event81900
Withdrew: Pregnancy0100
Withdrew: Lack of efficacy4700
Withdrew: Non-compliance with study drug1100
Withdrew: Lost to follow-up0300
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject4700
Withdrew: Miscellaneous0200
Apremilast Extension (Weeks 24 - 48)
Participant flow — Apremilast Extension (Weeks 24 - 48)
MilestonePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast-extension Phase: Placebo Then Apremilast 30 mgApremilast-extension Phase: Continued Apremilast 30 mg
Started0087162
Received 1 dose of investigational product0086160
Completed0077133
Not completed001029
Withdrew: Adverse event0026
Withdrew: Lack of efficacy0038
Withdrew: Lost to follow-up0041
Withdrew: Withdrawal by subject0017
Withdrew: Other0007

Outcome measures

PrimaryPercentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16

MDA is defined as tender joint counts (TJC) ≤ 1 and SJC ≤ 1 plus 3 of the following 5 criteria: 1. psoriasis body surface area (BSA) ≤ 3% 2. patient's pain visual analogue scale (VAS) on a 100 mm scale ≤ 15; where 0 indicates 'no pain' and 100 indicates 'pain as severe as can be imagined' 3. patient's global assessment of disease activity on a 100 mm scale ≤ 20, where 0 represents the lowest level of disease activity and 100 represents the highest. 4. physical function assessed by Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5; where 0 represents normal or no difficulty and 3 represents an inability to perform 5. enthesitis count ≤ 1 based on the Leeds Enthesitis Index; where 0 means nontender and 6 indicates 6 tender tendon insertions.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16
percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 1616.033.9
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0008 · Adjusted difference in proportions: 18.5 · 95% CI 8.9 to 28.1Apremilast - Placebo
SecondaryPercentage of Participants Who Achieved Remission or Low Disease Activity at Week 16 Based on Clinical Activity in Psoriatic Arthritis (cDAPSA)

The cDAPSA score is based on the numerical summation of 4 disease activity variables: tender and swollen joints, patient's global assessments of disease activity and assessment of pain (VAS). The cDAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. cDAPSA remission is defined as a DAPSA score ≤ 4 and low disease activity is defined as a cDAPSA score \> 4 but ≤ 13).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Remission or Low Disease Activity at Week 16 Based on Clinical Activity in Psoriatic Arthritis (cDAPSA)
percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants Who Achieved Remission or Low Disease Activity at Week 16 Based on Clinical Activity in Psoriatic Arthritis (cDAPSA)51.870.2
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0017 · Adjusted difference in proportions: 18.6 · 95% CI 7.0 to 30.2Apremilast - Placebo
SecondaryPercentage of Participants With SJC ≤ 1 at Week 16

The SJC was based on 66 joints and at week 16 is based on the sentinel joints (i.e., the joints that were affected at baseline). A SJC response is defined as a count ≤ 1.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With SJC ≤ 1 at Week 16
percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With SJC ≤ 1 at Week 1669.074.0
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.3539 · Adjusted difference in proportions: 5.1 · 95% CI -5.8 to 16.0Apremilast - Placebo
SecondaryPercentage of Participants With TJC ≤ 1 at Week 16

The TJC was based on 68 joints and at week 16 was based on the sentinel joints (i.e., the joints that were affected at baseline). A TJC response is defined as a count ≤ 1.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With TJC ≤ 1 at Week 16
percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With TJC ≤ 1 at Week 1644.466.2
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0003 · Adjusted difference in proportions: 22.1 · 95% CI 10.4 to 33.7Apremilast - Placebo
SecondaryPercentage of Participants With Patient's Global Assessments of Disease Activity Score of ≤ 20 mm in the VAS at Week 16

The Patient's Global Assessments of Disease Activity is an assessment of how active a participant's psoriatic arthritis was on average during the last week. It was assessed on a VAS ranging from 0 to 100 mm, with a higher score indicating more disease activity. A response is defined as a score ≤ 20 mm.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Patient's Global Assessments of Disease Activity Score of ≤ 20 mm in the VAS at Week 16
percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With Patient's Global Assessments of Disease Activity Score of ≤ 20 mm in the VAS at Week 1619.130.4
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0286 · Adjusted difference in proportions: 11.8 · 95% CI 1.7 to 22.0Apremilast - Placebo
SecondaryPercentage of Participants With an Assessment of Pain Score ≤ 15 mm in VAS at Week 16

The Patients Pain VAS is the participant's assessment of how much pain they had, on average, during the last week in their joints due to psoriatic arthritis. The VAS score ranges from 0 to 100 mm, with a higher score indicating more pain.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Assessment of Pain Score ≤ 15 mm in VAS at Week 16
percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With an Assessment of Pain Score ≤ 15 mm in VAS at Week 1613.129.4
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0022 · Adjusted difference in proportions: 16.3 · 95% CI 6.9 to 25.8Apremilast - Placebo
SecondaryChange From Baseline in Psoriatic Arthritis Impact of Disease 12-item for Clinical Trials (PsAID-12) Questionnaire Score at Week 16

The PsAID-12 Questionnaire is a 12-item, self-administered questionnaire that reflects the impact of psoriatic arthritis from the perspective of the participant. The overall score ranges from 0 (best status) to 10 (worst status), with a cut-off ≤ 4 representing patient-acceptable symptom state. Analysis was based on a mixed-effects model for repeated measures (MMRM), which included treatment group, time, treatment group by time interaction, prior/concomitant use of csDMARD (naive, prior use only, both prior and concomitant use) and baseline glucocorticosteroid use (yes/no) per IWRS data as factors, and baseline value as a covariate.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Psoriatic Arthritis Impact of Disease 12-item for Clinical Trials (PsAID-12) Questionnaire Score at Week 16
score on a scalePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Change From Baseline in Psoriatic Arthritis Impact of Disease 12-item for Clinical Trials (PsAID-12) Questionnaire Score at Week 16-0.42 ± 0.216-1.45 ± 0.178
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · MMRM · p = <0.0001 · Difference in ls means: -1.03 · 95% CI -1.48 to -0.59Apremilast - Placebo
SecondaryPercentage of Participants With a Good or Moderate Psoriatic Arthritis Disease Activity (PASDAS) Score at Week 16

The PASDAS is a weighted index comprising assessments of joints, function, acute-phase response, quality of life, and patient and physician VAS. The score range of the PASDAS is 0 - 10, with worse disease activity represented by higher scores. A good response is defined as a PASDAS score of ≤ 3.2 with improvement from baseline ≥ 1.6 points. A moderate response is defined as a PASDAS score \> 3.2 with improvement from baseline ≥ 1.6 points; or PASDAS score \< 5.4 with improvement from baseline ≥ 0.8 but \< 1.6 points.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Good or Moderate Psoriatic Arthritis Disease Activity (PASDAS) Score at Week 16
percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With a Good or Moderate Psoriatic Arthritis Disease Activity (PASDAS) Score at Week 1642.759.9
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0043 · Adjusted difference in proportions: 17.7 · 95% CI 5.7 to 29.7Apremilast - Placebo

Adverse events

Collected over Week 0 up to week 48 (end of extension phase), and a 4-week observational follow-up (up to 52 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Phase: Placebo0/104 (0%)6/104 (5.8%)18/104 (17.3%)
Placebo-controlled Phase: Apremilast 30 mg2/204 (1%)9/204 (4.4%)72/204 (35.3%)
Apremilast-exposure: Apremilast 30 mg During Placebo-controlled and Extension Phases2/291 (0.7%)15/291 (5.2%)103/291 (35.4%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast-exposure: Apremilast 30 mg During Placebo-controlled and Extension Phases
OsteoarthritisMusculoskeletal and connective tissue disorders0/1042/2042/291
Atrial fibrillationCardiac disorders1/1040/2041/291
CellulitisInfections and infestations1/1040/2041/291
UrosepsisInfections and infestations1/1040/2040/291
Troponin increasedInvestigations1/1040/2040/291
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1040/2040/291
Transient ischaemic attackNervous system disorders1/1040/2040/291
DepressionPsychiatric disorders1/1040/2040/291
Acute kidney injuryRenal and urinary disorders1/1040/2040/291
Hypertensive crisisVascular disorders1/1040/2040/291
Most frequent other events
Most frequent other events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast-exposure: Apremilast 30 mg During Placebo-controlled and Extension Phases
DiarrhoeaGastrointestinal disorders11/10447/20469/291
NauseaGastrointestinal disorders4/10422/20428/291
HeadacheNervous system disorders3/10416/20421/291
COVID-19Infections and infestations3/1047/20419/291

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Mean50.2 ± 13.0351.3 ± 12.2550.9 ± 12.51
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Female51118169
Male5485139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
American Indian or Alaska Native033
Asian145
Black or African American213
Native Hawaiian or Other Pacific Islander101
White99192291
Not Collected or Unknown235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Hispanic or Latino131629
Not Hispanic or Latino91185276
Not Reported123
08

Study locations

114 sites
  • Arizona Arthritis and Rheumatology Research, PLLC
    Mesa, Arizona 85202, United States
  • Covina Arthritis Clinic
    Covina, California 91722, United States
  • Encino Research Center
    Encino, California 91436, United States
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • Rheumatology Center of San Diego PC
    San Diego, California 92128, United States
  • East Bay Rheumatology Medical
    San Leandro, California 94578, United States
  • Millennium Clinical Trials
    Thousand Oaks, California 91360, United States
  • Robin K Dore MD Inc
    Tustin, California 92780, United States
  • Inland Rheumatology Clinical Trials Inc
    Upland, California 91786, United States
  • Denver Arthritis Clinic PC
    Denver, Colorado 80230, United States
  • Arthritis and Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Clinical Research of West Florida, Inc
    Clearwater, Florida 33765, United States
  • Center for Rheumatology, Immunology, and Arthritis
    Fort Lauderdale, Florida 33309, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • Integral Rheumatology and Immunology Specialists
    Plantation, Florida 33324, United States
  • Florida Center For Dermatology
    Saint Augustine, Florida 32080, United States
  • Clinical Research of West Florida Inc
    Tampa, Florida 33606-1246, United States
  • Carol and Frank Morsani Center for Advanced Health Care
    Tampa, Florida 33612, United States
  • Baycare Medical Group Inc
    Tampa, Florida 33614, United States
  • North Georgia Rheumatology Group PC
    Lawrenceville, Georgia 30046, United States
  • RC Rsearch Inc
    Hinsdale, Illinois 60521, United States
  • OrthoIllinois
    Rockford, Illinois 61114, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Clinical Trials Management LLC
    Metairie, Louisiana 70006, United States
  • Klein and Associates MD, PA - Cumberland
    Cumberland, Maryland 21502, United States
  • Klein and Associates MD PA
    Hagerstown, Maryland 21740, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Advanced Rheumatology PC
    Lansing, Michigan 48910, United States
  • Arthritis and Rheumatology Center of Michigan
    Lansing, Michigan 48910, United States
  • Clinical Research Institute of Michigan
    Saint Clair Shores, Michigan 48081, United States
  • Saint Paul Rheumatology PA
    Eagan, Minnesota 55121, United States
  • Arthritis, Rheumatic, and Back Disease Associates
    Voorhees Township, New Jersey 08043, United States
  • New York University Langone Medical Center
    New York, New York 10003, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Joint and Muscle Research Institute
    Charlotte, North Carolina 28204, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Paramount Medical Research and Consulting LLC
    Middleburg Heights, Ohio 44130, United States
  • Arthritis and Osteoporosis Center of Southwest Ohio
    Middletown, Ohio 45044, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Arthritis Group
    Philadelphia, Pennsylvania 19152, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Piedmont Arthritis Clinic
    Greenville, South Carolina 29601, United States
  • West Tennessee Research Institute, llc
    Jackson, Tennessee 38305, United States
  • Accurate Clinical Research Incorporated Baytown
    Baytown, Texas 77521, United States
  • Precision Comprehensive Clinical Research Solutions
    Colleyville, Texas 76034, United States
  • Texas Arthritis Center PA
    El Paso, Texas 79902, United States
  • West Texas Clinical Research
    Lubbock, Texas 79410, United States
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
  • Center for Clinical Studies
    Webster, Texas 92103, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98104, United States
  • Rheumatology and Pulmonary Clinic
    Beckley, West Virginia 25801, United States
  • West Virginia Research Institute
    Morgantown, West Virginia 26505, United States
  • West Virginia Research Institute
    South Charleston, West Virginia 25309, United States
  • Universitaetsklinikum Allgemeines Krankenhaus Wien Universitaetsklinik fur Innere Medizin I
    Vienna, 1090, Austria
  • Krankenhaus Hietzing
    Vienna, 1130, Austria
  • Centre Hospitalier Universitaire Brugmann
    Brussels, 1020, Belgium
  • Hopital Erasme
    Brussels, 1070, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Ziekenhuis Netwerk Antwerpen Jan Palfijn
    Merksem, 2170, Belgium
  • Manitoba Clinic
    Winnipeg, Manitoba R3A 1M3, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • Dr Sabeen Anwar Medicine Professional Corporation
    Windsor, Ontario N8X 1T3, Canada
  • Institut de Rhumatologie de Montreal
    Montreal, Quebec H2L 1S6, Canada
  • Centre Hospitalier Regional dOrleans
    Orléans, 45067, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Assistance Publique- Hopitaux de Paris AP-HP
    Paris, 75013, France
  • CH Toulouse Hopital Pierre-Paul Riquet
    Toulouse, 31059, France
  • Praxis fur Rheumatologie - Amberg
    Amberg, 92224, Germany
  • Kerckhoff-Klinik gGmbH
    Bad Nauheim, 61231, Germany
  • Charite - Universitaetsmedizin Berlin, Campus Mitte
    Berlin, 10117, Germany
  • Universitaetsklinikum Duesseldorf
    Düsseldorf, 40225, Germany
  • Service Rheuma Erfurt
    Erfurt, 99096, Germany
  • Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt/Main
    Frankfurt am Main, 60590, Germany
  • Universitatsklinikum Freiburg
    Freiburg im Breisgau, 79106, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, 44649, Germany
  • Universitaetsklinikum Tuebingen
    Tübingen, 72076, Germany
  • AO Ospedale Policlinico Consorziale Di Bari
    Bari, 70124, Italy
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Universita degli studi Messina
    Messina, 98125, Italy
  • IRCCS Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Naples, 80131, Italy
  • Policlinico San Matteo Universita Di Pavia
    Pavia, 27100, Italy
  • Azienda Ospedaliera Universitaria Pisana
    Pisa, 56126, Italy
  • Fondazione Policlinico Tor Vergata
    Rome, 00133, Italy
  • Humanitas Research Hospital Humanitas Mirasole
    Rozzano MI, 20089, Italy
  • Azienda Ospedaliera Universitaria Integrata di Verona Ospedale G B Rossi Borgo Roma
    Verona, 37126, Italy
  • Medisch Spectrum Twente
    Enschede, 7512 KZ, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CN, Netherlands
  • Kazan State Medical University
    Kazan', 420097, Russia
  • Kursk Regional Clinical Hospital
    Kursk, 305007, Russia
  • Research Institute of Rheumatology named after V A Nasonova
    Moscow, 115522, Russia
  • Moscow Regional Research Institute n a Vladimirsky
    Moscow, 129110, Russia
  • Research Institute of Clinical and Experimental Lymphology
    Novosibirsk, 630061, Russia
  • Republican Hospital na VA Baranov
    Petrozavodsk, 185019, Russia
  • Municipal Budgetary Healthcare Institution City Emergency Hospital
    Rostov-on-Don, 344029, Russia
  • Mechnikov North-Western State Medical University
    Saint Petersburg, 191015, Russia
  • Medical Center Sanavita
    Saint Petersburg, 197341, Russia
  • Tomsk Regional Clinical Hospital
    Tomsk, 634063, Russia

Showing the first 100 of 114 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Coates LC, Gladman DD, Merola JF, Mrowietz U, Armstrong A, Baraliakos X, Tillett W, Kishimoto M, Reddy J, Teng L, Amouzadeh H, Deignan C, Mease PJ, Gossec L. Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST. Rheumatology (Oxford). 2026 Jun 30;65(7):keag351. doi: 10.1093/rheumatology/keag351. PubMed 42384964 ↗
  • Gossec L, Coates LC, Gladman DD, Aelion JA, Vasandani J, Pinter A, Merola JF, Kavanaugh A, Reddy J, Wang R, Brunori M, Klyachkin Y, Deignan C, Mease PJ. Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial. Ann Rheum Dis. 2024 Oct 21;83(11):1480-1488. doi: 10.1136/ard-2024-225833. PubMed 39164067 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Dec 2022, 47 months.

Results were first posted in Jan 2024, 1 year after primary completion.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2018
First posted
Nov 20, 2018
StartActual
Dec 31, 2018
Primary completionActual
Dec 19, 2022
CompletionActual
Jul 5, 2023
Results first posted
Jan 5, 2024
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03747939
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Dec 31, 2018
Primary completion
Dec 19, 2022
Completion
Jul 5, 2023
Results posted
Jan 5, 2024
Last update
Sep 11, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion